P-130 Short course pelvic radiotherapy for localized and oligometastatic rectal adenocarcinoma: The Mayo Clinic experience
S. Lee(Tuen Mun Hospital), Terence T. Sio(The University of Texas MD Anderson Cancer Center), David A. Etzioni(Phoenix (United States)), Joleen M. Hubbard(Rutgers, The State University of New Jersey), Sunil Krishnan(Smith Family), Amit Merchea(Jacksonville College), William G. Rule(Mayo Clinic in Arizona), Nathan Y. Yu(Mayo Clinic Hospital), M. Neben Wittich(Mayo Clinic), Christopher L. Hallemeier(Mayo Clinic in Arizona), Daniel H. Ahn(Mayo Clinic Hospital), Michael G. Haddock(Mayo Clinic in Arizona), Tanios Bekaii‐Saab(WinnMed), Kellie L. Mathis(Twitter (United States)), Kenneth W. Merrell(Mayo Clinic), Jonathan B. Ashman(Mayo Clinic in Arizona), Zhaohui Jin(XinHua Hospital), Amit Mahipal(Dana-Farber Cancer Institute), Nitin Mishra(Mayo Clinic), Brady Laughlin(WinnMed)
Cited by 0
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530